INTRODUCTION
============

Pain is a common non-motor symptom of Parkinson's disease (PD) patients, is often associated with depression \[[@b1-kjp-33-090]\], induces poorer health-related quality of life \[[@b2-kjp-33-090]\] and impairs patient autonomy \[[@b3-kjp-33-090]\]. Valuations on its impact vary from 29% \[[@b4-kjp-33-090]\] to 85% \[[@b5-kjp-33-090]\], although we can assert that it represents an important issue for the majority of PD patients. Oddly enough, there are virtually no peer reviews \[[@b6-kjp-33-090]\] and no extended monographs published on the treatment of non-motor symptoms by the Movement Disorder Society that are based on evidence \[[@b7-kjp-33-090]\]. PD is clearly established when neuronal loss within the compact area of the sub-stantia nigra reaches 60% to 70% and when dopamine inside the striatum is approximately 80% compared to normal controls. In its initial stages (*i.e.*, the pre-motor stage), some unusual non-motor symptoms may be present that progress into motor symptoms over time (*i.e.*, the motor stage).

Manifest symptoms during the pre-motor stage include depression, pain, hyposmia (reduced sense of smell), constipation, rapid eye movement sleep behavior disorders, and seborrheic dermatitis \[[@b8-kjp-33-090]\]. During this particular phase, when facing stress, patients may also show transitory motor symptoms like slight intermittent and asymmetric movements of the limbs, lack of gestures and expressions, tiredness, or perspiration issues during heat waves \[[@b9-kjp-33-090]\]. During the preclinical stage, pain is one of the early symptoms of PD. Primary pain \[[@b10-kjp-33-090]\] or secondary pain may be due to lack of physical activity. Occasionally, pain can affect one shoulder, which is why many patients are mistakenly diagnosed with "painful shoulder syndrome".

Approximately 25% of patients show pain-related (throbbing or uncomfortable) sensations in different body areas. These types of PD-associated pains have been classified as central pain, with some possible alterations of the intrala-minar nuclei circuits inside the thalamus itself (because they may be affected by the disease), and as ascendant sensitive systems (discriminatory and palpable perceptions) that may be related to an unadapted motor-based response \[[@b11-kjp-33-090]\]. At least two-thirds of PD patients report feeling pain to some degree \[[@b12-kjp-33-090]\]; the etiology of this pain appears to rely on multiple factors. Pain is present during the end-stages of PD, which includes dyskinesias, dystonias, off-periods, and central nervous system-sensitive disorders. Pain is one of the disorders that most significantly affects quality of life \[[@b13-kjp-33-090]\]. The aim of this study was to investigate the clinical characteristics of pain in patients with PD.

MATERIALS AND METHODS
=====================

1. Participants
---------------

A total of 250 patients diagnosed with PD were included in this cross-sectional study. Inclusion criteria were as follows: patients of either sex, aged = 30; with a previous idiopathic PD diagnosis; with one permanent, full-time care-giver; and who provided informed consent to participate in the study. Exclusion criteria included noncompliance to one of the inclusion criteria, and a medical or psychiatric comorbidity precluding an accurate evaluation of PD. Patients included in the present study were then "newly-diagnosed" patients, or considered patients with idiopathic PD according to the criteria established by the UK Parkinson's Disease Society Brain Bank for PD stages I--IV.

2. Methodology
--------------

The study protocol was reviewed and approved by the Vithas Xanit International Hospital Ethics Committee (IRB No. 11-348). Participants were recruited from the hospital's neurology department and signed an informed consent form prior to inclusion in the study. A neurologist and a neuropsychologist belonging to the movement disorders unit of the neurosciences area of the aforementioned hospital evaluated patients prior to their inclusion. Relevant data collected from PD patients were obtained from their personal medical history.

We used the following scales: The scales for outcomes in Parkinson's disease (SCOPA)-motor \[[@b14-kjp-33-090]\], SCOPA-AUT (autonomic) \[[@b15-kjp-33-090],[@b16-kjp-33-090]\], SCOPA-COG (cognition) \[[@b17-kjp-33-090],[@b18-kjp-33-090]\], modified Parkinson's psychosis rating scale \[[@b19-kjp-33-090]\], Hoehn and Yahr \[[@b20-kjp-33-090]\], and the hospital anxiety and depression scale \[[@b21-kjp-33-090]\]. We also included "visual analogue scale" (VAS) testing because of its ease of use, which was quickly adapted to measure pain intensity. A 24-item questionnaire, previously used by the Santos-García et al. \[[@b3-kjp-33-090]\] research group to evaluate pain types was used to identify, classify, and analyse pain; a ready-to-select pain-type list is included in this questionnaire. We believe that the inclusion of such different pain-types and frequencies over time is a rather unique advantage of our study.

Data were analysed with IBM SPSS ver. 22.0 (IBM Corp., Armonk, NY) and quantitative variables are expressed as means ± standard deviation, or with the absolute frequency (percentages). Spearman's correlation coefficient was also used to measure the strength of association between some quantitative random variables. *P* \< 0.05 was considered statistically significant.

RESULTS
=======

We included 250 patients with PD whose clinical and epidemiological data are summarized in [Table 1](#t1-kjp-33-090){ref-type="table"}. The prevalence of pain in these patients was found to be 82%. Distributions following the Hoehn and Yahr classification were as follows: stage 1 (23.8%), stage 2 (49.4%), stage 3 (20.4%), stage 4 (4.7%), and stage 5 (0.7%). The following treatment distributions were observed during the initial treatment phase: levodopa (L; 35.4%), dopaminergic agonist (DA; 33.7%), polypharmacy (10.8%), other treatment (9.3%), and lastly, L supplemented with agonists (7.1%).

With respect to the initial motor situation of PD patients during their first evaluation, we assumed the non-fluctuants to be in an "on stage", and included the fluctuants into an "on" or "off" group according to the study protocol. Under these premises, approximately 96% were considered as "on" patients and 4% as "off" patients. [Table 2](#t2-kjp-33-090){ref-type="table"} shows the descriptive statistics derived from the scales used in the study.

Pain experienced by PD patients is mainly represented by the electrical current type (64%) and the itching type (4%). These results have been drawn from PD patients' answers to item 21 of the pain questionnaire ([Table 3](#t3-kjp-33-090){ref-type="table"}). The frequency of these pain types was found to be the following: patients feeling only one (12%), two (16%), or three (72%)---Some PD patients responded feeling three or more pain types. Answers were classified under three categories only because we believed that differentiating over three types would be too complicated---different pain types (2.60 ± 0.63) \[[@b3-kjp-33-090]--[@b5-kjp-33-090]\]. PD pain differ between the sexes in pain-type frequency: females (1 type: 14.28%; 2 types: 7.14%; 3 types: 78.57%), males (1 type: 9.09%; 2 types: 27.27%; 3 types: 63.63%; n = 250; mean: 2.60; [Fig. 1](#f1-kjp-33-090){ref-type="fig"}). There is a higher prevalence of one singular pain type in females than in males; however, males present a higher frequency of two pain types than do females.

Quantitative pain perception in PD patients provides data on pain frequency and shows some intense pain (VAS score: 55.6 ± 29.3) with quite frequent events. Pain intensity was also evaluated (mean: 61.00 ± 21.54). Gradual pain characteristics are shown in percentages in [Fig. 2](#f2-kjp-33-090){ref-type="fig"}.

PD duration was also found to be linked to the frequency of intense pain (R = 0.393; *P* \< 0.05). To summarize, it seems that disease duration is a crucial determinant of pain severity. With results obtained from answers to item 11 of the questionnaire, dopaminergic treatment can be confirmed as an efficient intervention to control pain in only 48% of patients. PD patients that fail to respond to dopaminergic treatments to mitigate their pain are often administered general analgesics to positive effect: standard analgesic treatments were found to reduce participants' pain in 78.8% of cases.

Another interesting fact is that PD patients feel pain in different ways depending on the implementation of the dopaminergic treatment. All patients feel some burning pain when administered L and DA. When treatments are combined, patients feel an increase in throbbing and electrical discharge-like pain. We have only included the percentages ranging from 75%--100% ([Fig. 3](#f3-kjp-33-090){ref-type="fig"}) for the L, DA, L + DA, and combined treatments.

Most patients (79.2%) assert that their pain is related to their PD, while 20.8% say it has nothing to do with it. Our results show that PD patients who feel pain are those that have been suffering from PD for over three months (3.72 ± 0.79 mo). Approximately 32% of patients felt pain prior to their PD diagnosis, and approximately 60% of patients had already reported their pain to their neurology specialists.

With regard to the body areas affected by pain, 84% of patients localize it to the lower back area, with 27% of these feeling some kind of descending cramp pain towards the lower limbs. The average number of painful areas reported by PD patients was three. Pain located in different body areas was present in 20%--60% of cases, with the highest prevalence felt in the back and lower limbs ([Fig. 4](#f4-kjp-33-090){ref-type="fig"}).

We added some supplementary statistics regarding the body areas most affected by pain in PD patients based on the Hoehn and Yahr classification \[[@b20-kjp-33-090]\]. The early stages include phases I and II, and the advanced stages include phases III--V ([Fig. 5](#f5-kjp-33-090){ref-type="fig"}).

PD patients reported higher pain levels in their most PD-affected body areas. Approximately 84% of participants in the study reported feeling pain when they were more stationary, still, clumsier, stiffer, or shakier, which is when they were more affected by some kind of motor-related alteration. PD-related pain surfaces at different times throughout the day. Our results reveal that some PD patients felt pain constantly (28%), some when they were clumsier or "off" (36%)---which is when they are more affected by their PD---and some intermittently throughout the day (24%). Thirty-two percent of the PD patients in our study experienced pain throughout the entire day, 24% during the night, and 16% early in the morning or at another time point. Approximately 60% of participants reported feeling pain, including pressure in one of their upper or lower limbs, when their muscles or joints felt stiffer, while 40% of them reported no correlation with stiffness. Approximately 76% of PD patients felt pain during dyskinesia events, while 24% did not.

DISCUSSION
==========

The prevalence of pain in our study (82%) is quite similar to findings of other studies \[[@b3-kjp-33-090],[@b22-kjp-33-090]--[@b27-kjp-33-090]\], since minor prevalence data analysis must consider the number of cases included \[[@b28-kjp-33-090]\]. Our results, however, differ from those of some studies, such as Djaldetti et al. \[[@b29-kjp-33-090]\], where the main pain is described as burning and itching. However, their results did corroborate ours with respect to the prevalence of the burning type of pain in PD patients.

A review of the literature found no detailed analysis of the perceived pain \[[@b30-kjp-33-090]--[@b34-kjp-33-090]\]; most studies do not account extensively for these aspects \[[@b35-kjp-33-090]\]. Some studies, however, have described pain using a much more syndrome-based terminology, which is interpreted by researchers and specialists in a quite similar way as that used for the advanced stages, namely musculoskeletal (70%), dystonic (40%), radicular neuropathic (20%), and central neuropathic (10%) \[[@b23-kjp-33-090]\]. Yet, in the reviews published thus far, the most frequent descriptions of PD patients' pain reflect some form of continuous "burning", "itching", "stabbing", "aching", or "tingling" sensation \[[@b23-kjp-33-090],[@b27-kjp-33-090],[@b29-kjp-33-090]--[@b31-kjp-33-090]\], which explains our use of this terminology in our study. These previous works, and ours, have generally focussed on the representation and importance of the alterations of the senses described herein. Furthermore, we, like they, have found pain to be most commonly located in the motor areas most affected by PD, particularly during the off-period, with no specific explorable deficit in the senses, whether dermatome-limited or neurologically diffuse. PD patients can feel different types of pain. In this study, we quantified the frequency of these different types of pain after studying the answers to item 21 in the pain questionnaire.

PD patients who feel pain experience between one and three (or more) types of pain. According to our results, the female sex is more highly associated with pain in PD. This had already been shown in previous studies \[[@b22-kjp-33-090]\] where being female acted as an independent predictor of pain. In other, less exhaustive studies, no correlation was found between pain and sex \[[@b27-kjp-33-090],[@b31-kjp-33-090]--[@b33-kjp-33-090]\], age, evolution over time, or motor stage \[[@b22-kjp-33-090],[@b31-kjp-33-090]\]. As previously mentioned, our classification is based on anatomy (because that is how patients refer to their pain), whereas those of other authors is based on syndromes (as referred to by the specialists, so that patients "learn to decipher" their pain). Wasner and Deuschl \[[@b36-kjp-33-090]\] recommended that pain be classified as either nociceptive (musculoskeletal, visceral, or cutaneous) or neuropathic (peripheral or central). On the other hand, Chaudhuri and Schapira \[[@b37-kjp-33-090]\] differentiated the types of pain as follows: musculoskeletal pain, chronic pain related to PD, pain related to fluctuations, nighttime pain, orofacial pain, pain affecting peripheral extremities, and abdominal pain. The pain classification established by Ford \[[@b38-kjp-33-090]\] remains one of the more commonly mentioned, because it identifies five fundamental types of pain in PD that are based on origin and on treatment perspective. Valkovic et al. \[[@b34-kjp-33-090]\] recently classified pain in PD into five categories using a syndrome-based classification. Our study holds a particular strength because it used a clinical classification that resembles much more closely the sensations described by the patients themselves.

As concerns the time of day when PD patients were most aware of their pain, we should point out that none of our patients explicitly expressed feeling pain early in the morning, which conflicts with the idea that fluctuation-denominated "early-morning dystonia" is painful. PD patients feeling pain indicated its presence as constant throughout the day (32%) or as occurring at nighttime (24%), when waking up (12%), in the afternoon (8%), in the morning and afternoon (84%), in the afternoon and evening (4%), and while waking up combined with another time during the day (16%). New treatments used to treat PD are now available that may help alleviate these symptoms due to the glutamate action-based mechanisms, like that of safinamide, which has a dual action (monoamine oxidase B inhibitor and glutamate) \[[@b39-kjp-33-090]\].

To conclude, these results suggest that pain has a substantial impact on the motor and non-motor aspects of patients with PD regardless of the clinical characteristics of the pain. Dopaminergic treatment proved quite effective to control pain in approximately half of these patients. The present study confirms an existing link between pain, its evolution over time, the female gender, its multi-modal character, and PD's wide variety of symptoms. Our results demonstrated that the pain perceived by PD patients is mainly described as a type of electrical current, and least frequently described as a type of itching, compared to other studies where the pain was described as a burning and itching sensation. Our classification is comparatively more innovative because it is anatomy-based, whereas those of other authors are syndrome-based. Furthermore, based on the results of this study and of previous studies, pain was significantly influenced by depression and parkinsonian motor impairment.
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###### 

Basic Sample Characteristics (n = 250)

  Characteristic           Value                
  ------------------------ -------------------- ----------------------
  Sex                      Male                 110 (44.0)
                           Female               140 (56.0)
  Mean age (yr)                                 67.4 ± 10.1 (44--87)
  Civil status             Married/partner      170 (68.0)
                           Single/widower       60 (24.0)
                           Divorced             10 (4.0)
  Environment              Own residence        240 (96.0)
                           State centres        10 (4.0)
  Surroundings             Urban                200 (80.0)
                           Rural                50 (20.0)
  Educational attainment   Primary school       150 (60.0)
                           ≥ Secondary school   100 (40.0)
  Age of PD onset (yr)                          58.0 ± 11.9 (24--85)
  PD duration (yr)                              7.1 ± 5.8 (1--45)
  HADS                     Depression           180 (72.0)
                           No depression        70 (28.0)

Values are presented as number (%) or mean ± standard deviation (range).

PD: Parkinson's disease, HADS: hospital anxiety and depression scale.

###### 

Health Characteristics of the Sample (n = 250)

  Scale                 Value
  --------------------- ------------------------
  Total SCOPA-motor     25.04 ± 13.50 (6--54)
  Motor exploration     12.75 ± 5.49 (3--22)
  Daily activities      8.16 ± 4.43 (1--18)
  Motor complications   2.48 ± 2.34 (0--7)
  Total SCOPA-AUT       23.58 ± 14.18 (2--65)
  Total SCOPA-COG       23.06 ± 7.35 (3--35)
  MPPRS                 2.50 ± 2.00 (0--7)
  Hoehn and Yahr        2.56 ± 0.87 (1--5)
  HADS                  16.48 ± 8.61 (0--38)
  Total pain            38.08 ± 26.96 (0--100)

Values are presented as mean ± standard deviation (range).

SCOPA: the scales for outcomes in Parkinson's disease, AUT: autonomic, COG: cognition, MPPRS: modified Parkinson's psychosis rating scale, HADS: hospital anxiety and depression scale.

###### 

Pain Types Frequencies

  Pain types             Value
  ---------------------- -------------
  Generalized            0.52 ± 1.80
  Hot and cold           0.60 ± 1.80
  Palpitations           0.12 ± 0.33
  Itching                0.04 ± 0.20
  Oppressive             0.24 ± 0.43
  Colicky                0.00 ± 0.00
  Weakness, drowsiness   0.24 ± 0.43
  Numbness, tingling     0.40 ± 0.50
  Burning                0.16 ± 0.37
  Internal               0.40 ± 0.50
  Tension                0.32 ± 0.47
  Throbbing              0.52 ± 0.51
  Electrical discharge   0.64 ± 1.80

Values are presented as mean ± standard deviation.
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